333 Bay St, Suite 2400, Bay Adelaide Ctr, Box 20, Toronto, ON
Year called to bar: 1997 (ON)
Timothy Squire is one of Canada's leading Life Sciences Industry Specialists. With his extensive regulatory and commercialization experience, Tim has become a trusted advisor to stakeholders in the drug, medical device, natural health product, cosmetic and food industries in Canada and from around the world. Tim’s practice is devoted to the Life Sciences industry, and he is the former Chair of the firm's International Life Sciences Industry Group. He adds substantial bench strength given his extensive knowledge and experience across the entire health product lifecycle. Tim has become a trusted advisor to many stakeholders in the drug, medical device, natural health product, cosmetic and food industries in Canada and around the world due to his expertise and commitment to client service. Tim's regulatory practice covers all aspects of health product regulation and market access, and he is one of the few specialists in Canada regularly called upon to help solve complex health product compliance and enforcement issues. To this end, Tim frequently communicates with Health Canada and other federal and provincial regulators on our clients’ behalf.
On October 21, 2015, Concordia Healthcare Corp. (“Concordia”), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, acquired UK-based Amdipharm Mercury Limited (“AMCo”) from Cinven Ltd, a leading European private equity firm, for approximately US$3.3 billion (the “Acquisition”) paid through a combination of cash and the issuance of 8.49 million common shares of Concordia.
